A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)

NCT03745820 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

195

Enrollment

INDUSTRY

Sponsor class

Conditions

Cognitive Impairment Associated With Schizophrenia

Interventions

DRUG: BIIB104
OTHER: Placebo

Sponsor

Biogen